Dabigatran and warfarin: comparative analysis of safety and cost.

被引：0
|
作者：
Vakil, Niyati H. [1 ]
Leber, Molly [1 ]
Bliss, Gina [1 ]
Yazdi, Marina [1 ]
机构：
[1] Yale New Haven Med Ctr, New Haven, CT 06504 USA
来源：
PHARMACOTHERAPY | 2012年 / 32卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
6E
引用
收藏
页码：E179 / E179
页数：1
相关论文
共 50 条
  • [31] Comparative Effectiveness and Safety of Dabigatran vs. Warfarin in Patients With Atrial Fibrillation - Evidence From Real World Practice
    Tsadok, Meytal Avgil
    Jackevicius, Cynthia A.
    Essebag, Vidal
    Eisenberg, Mark J.
    Rahme, Elham
    Humphries, Karin H.
    Tu, Jack V.
    Pilote, Louise
    CIRCULATION, 2013, 128 (22)
  • [32] THE COST-EFFECTIVENESS OF APIXABAN COMPARED TO WARFARIN, ASPIRIN, RIVAROXABAN AND DABIGATRAN IN IRELAND
    Kelly, J.
    Griffith, G.
    Fortune, P.
    Lister, S.
    VALUE IN HEALTH, 2013, 16 (07) : A529 - A529
  • [33] COST-EFFECTIVENESS OF DABIGATRAN VERSUS WARFARIN IN ATRIAL FIBRILLATION MANAGEMENT IN COLOMBIA
    Alfonso-Cristancho, R.
    Herran, S.
    Caicedo, M.
    Gomez, E.
    VALUE IN HEALTH, 2011, 14 (07) : A536 - A537
  • [34] Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
    Davidson, Thomas
    Husberg, Magnus
    Janzon, Magnus
    Oldgren, Jonas
    Levin, Lars-Ake
    EUROPEAN HEART JOURNAL, 2013, 34 (03) : 177 - 183
  • [35] Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
    Freeman, James V.
    Zhu, Ruo P.
    Owens, Douglas K.
    Garber, Alan M.
    Hutton, David W.
    Go, Alan S.
    Wang, Paul J.
    Turakhia, Mintu P.
    ANNALS OF INTERNAL MEDICINE, 2011, 154 (01) : 1 - U129
  • [36] Cost-Utility Analysis of Dabigatran and Warfarin for Stroke Prevention Among Patients With Nonvalvular Atrial Fibrillation in India
    Aghoram, Rajeswari
    Kumar, S. Mathan
    Rajasulochana, Subramania Raju
    Kar, Sitanshu Sekhar
    Aggarwal, Rakesh
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 31 : 119 - 126
  • [37] COST-EFFECTIVENESS ANALYSIS COMPARING DABIGATRAN AND ADJUSTED-DOSE WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION
    Zhao, Y.
    Lim, L.
    Coleman, C., I
    VALUE IN HEALTH, 2011, 14 (03) : A41 - A41
  • [38] Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation
    Dzeshka, Mikhail S.
    Lip, Gregory Y. H.
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (01) : 45 - 62
  • [39] Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
    Chan, Yi-Hsin
    See, Lai-Chu
    Tu, Hui-Tzu
    Yeh, Yung-Hsin
    Chang, Shang-Hung
    Wu, Lung-Sheng
    Lee, Hsin-Fu
    Wang, Chun-Li
    Kuo, Chang-Fu
    Kuo, Chi-Tai
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (08):
  • [40] Efficacy and safety of dabigatran versus warfarin from the RE-LY trial
    Avezum, Alvaro
    de Figueiredo Oliveira, Gustavo Bernardes
    Diaz, Rafael
    Gonzalez Hermosillo, Jesus Antonio
    Oldgren, Jonas
    Ripoll, Ernesto Ferreiros
    Noack, Herbert
    Piegas, Leopoldo Soares
    Connolly, Stuart J.
    OPEN HEART, 2018, 5 (01):
12345